In vitro and in vivo inhibition of proangiogenic retinal phenotype by an antisense oligonucleotide downregulating uPAR expression
Matteo Lulli ; Maurizio Cammalleri ; Irene Granucci ; et al. ; - ASI Sponsor
Aug - 2017
DOI: 10.1016/j.bbrc.2017.06.150

journal : Biochemical and Biophysical Research Communications

Volume : 490 ; Issue : 3
type: Article Journal

Neoangiogenesis is the main pathogenic event involved in a variety of retinal diseases. It has been recently demonstrated that inhibiting the urokinase-type plasminogen activator receptor (uPAR) results in reduced angiogenesis in a mouse model of oxygen-induced retinopathy (OIR), establishing uPAR as a therapeutic target in proliferative retinopathies. Here, we evaluated in cultured human retinal endothelial cells (HRECs) and in OIR mice the potential of a specific antisense oligodeoxyribonucleotide (ASO) in blocking the synthesis of uPAR and in providing antiangiogenic effects.uPAR expression in HRECs was inhibited by lipofection with the phosphorotioated 5′-CGGCGGGTGACCCATGTG-3′ ASO-uPAR, complementary to the initial translation site of uPAR mRNA. Inhibition of uPAR expression via ASO-uPAR was evaluated in HRECs by analyzing VEGF-induced tube formation and migration. In addition, the well-established and reproducible murine OIR model was used to induce retinal neovascularization in vivo. OIR mice were injected intraperitoneally with ASO-uPAR and retinopathy was evaluated considering the extent of the avascular area in the central retina and neovascular tuft formation.The ASO-uPAR specifically decreased uPAR mRNA and protein levels in HRECs and mitigated VEGF-induced tube formation and cell migration. Noteworthy, in OIR mice ASO-uPAR administration reduced both the avascular area and the formation of neovascular tufts.In conclusion, although the extrapolation of these experimental findings to the clinic is not straightforward, ASO-uPAR may be considered a potential therapeutic tool for treatment of proliferative retinal diseases

keywords : Human retinal endothelial cells; Retinal diseases; VEGF

Notes : AcknowledgementsThis work was supported by the Italian Space Agency (ASI), grant numbers I/014/11/0 and 2016-6-U.0.